Genomatica Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2021 | $119 M | No. 3 | $50 to $250 million | equity | SEC | |
| Feb 2014 | $7 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Jul 2012 | $46 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Genomatica Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2021).
SEC Form D · Aug 2021
The industry group it chose in its notices: Other Technology.
SEC Form D · Aug 2021
That is all the official record says: Genomatica Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: the address on record now leads to another company's site.
Investors#
No investor of Genomatica Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 12 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Carlos A. Cabrera | Executive officer | Aug 2021 |
| Christophe Schilling | Executive officer | Aug 2021 |
| David Bendsen Muldoon | Executive officer | Aug 2021 |
| Rasmus Bendsen von Gottberg | Executive officer | Aug 2021 |
| Thomas Bendsen McDonald | Executive officer | Aug 2021 |
| Jeff J.G. Lievense | Executive officer | Mar 2014 |
| Mark J.G. Burk | Executive officer | Mar 2014 |
| Michael J.G. Keane | Executive officer | Mar 2014 |
| William H. Baum | Executive officer | Mar 2014 |
| Anders Bendsen Spohr | Director | Aug 2021 |
| Carlos A. Cabrera | Director | Aug 2021 |
| Christophe Schilling | Director | Aug 2021 |
| Craig A. Binetti | Director | Aug 2021 |
| Eli A. Casdin | Director | Aug 2021 |
| Jason A. Kelly | Director | Aug 2021 |
| Geoff H. Duyk | Director | Mar 2014 |
| Josh H. Green | Director | Mar 2014 |
| Just J.G. Jansz | Director | Mar 2014 |
| Leighton J.G. Read | Director | Mar 2014 |
| Thomas J.G. Huot | Director | Mar 2014 |
| Warren H. Clark | Director | Mar 2014 |
| William H. Baum | Director | Mar 2014 |
| Michael J.G. Savage | Director | Aug 2012 |
About
American biotechnology company.